Integration of HapMap-based SNP pattern analysis and gene expression profiling reveals common SNP profiles for cancer therapy outcome predictor genes

Cell Cycle

Volumn 5, Issue 22, 2006, Pages 2613-2625

  Glinsky, Gennadi V ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

BMI1 gene; HapMap; Microarray analysis; Polycomb pathway; Self renewal; SNP profiling; Stem cells; Survival predictor

Indexed keywords

ARTICLE; CANCER THERAPY; CELL CYCLE; DISEASE PREDISPOSITION; DNA FINGERPRINTING; EVIDENCE BASED MEDICINE; GENE CONTROL; GENE EXPRESSION; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MARKER GENE; MICROARRAY ANALYSIS; ONCOGENE; ONCOGENE MYC; ONCOGENE RAS; POPULATION DIFFERENTIATION; PROGNOSIS; TREATMENT FAILURE;

EID: 33751235250     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.5.22.3498     Document Type: Article

References (10)

1. The international HapMap consortium: A haplotype map of the human genome. Nature 2005; 437:1299-320.
2. Glinsky GV, Berezovska OP, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. Journal of Clinical Investigation 2005; 115:1503-21.
3. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffmann RM, Gerald WL. Expression profiling predicts clinical outcome of prostate cancer. Journal of Clinical Investigation 2004; 113:913-23.
4. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005; 8:393-406.
5. Morley M, Molony CM, Weber TM, Devlin JL, Ewens KG, Spielman RS, Cheung VG. Genetic analysis of genome-wide variation in human gene expression. Nature 2004; 430:743-7.
6. Cheung VG, Spielman RS, Ewens KG, Weber TM, Morley M, Burdick JT. Mapping determinants of human gene expression by regional and genome-wide association. Nature 2005; 437:1365-9.
7. Mouse genome sequencing consortium: Initial sequencing and comparative analysis of the mouse genome. Nature 2002; 420:520-62.
8. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson Jr JA, Marks JR, Dressman HK, West M, Nevins JR. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439:353-7.
9. Glinsky GV. Genomic models of metastatic cancer: Functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated Polycomb Group (PcG) protein chromatin silencing pathway. Cell Cycle 2006; 5:1208-16.
10. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530-6.